|
日漲幅為1.13%，漲停的有3隻；下跌的有38隻。今日上漲的有9個，淨流出資金為40.19億元，漲幅分別為2.78%、立航科技， 資金麵上看，淨流出資金分別為1.24億元、該行業資金淨流入的個股有81隻 ，股市有風險，淨流入資金超3000萬元的有8隻，電力設備，淨流入資金為8.36億元。全天淨流入資金17.09億元，傳媒等行業。睿創微納 ，2.22%。國防軍工行業位居今日漲幅榜第二。 國防軍工行業今日上漲1.50%，該行業今日 國防軍工行業資金流入榜 代碼簡稱今日漲跌幅（%）今日換手率（%）主力資金流量（萬元）600072中船科技7.779.0419555.50300875捷強裝備20.0015.378801.41603261立航科技10.0034.746872.49300775三角防務4.804.215953.89002625光啟技術4.125.504950.90002389航天彩虹6.183.804747.40000768中航西飛1.960.703765.63688297中無人機6.534.683101.83002465海格通信0.091.662693.88600685中船防務1.771.802659.45600316洪都航空4.742.102658.43300719安達維爾19.9734.172577.71600760中航沈飛1.640.692269.31600893航發動力0.860.562224.14300034鋼研高納6.715.561994.01601890亞星錨鏈3.113.211929.45300008天海防務4.032.881788.29300696愛樂達12.819.431761.64688122西部超導1.701.041749.51600862中航高科2.422.271710.14 國防軍工行業資金流出榜 代碼簡稱今日漲跌幅（%）今日換手率（%）主力資金流量（萬元）300045華力創通-4.779.71-12405.70600765中航重機1.224.18-4784.13688002睿創微納-2.702.56-3100.58300065海蘭信-3.523.22-2439.05002446盛路通信-2.084.21-2114.63600879航天電子0.551.69-1933.21600150中國船舶0.881.12-1470.63002023海特高新3.578.05-1237.37688629華豐科技-6.1412.41-1195.09300699光威複材1.882.20-1139.31300474景嘉微-1.292.16-1138.23688522納睿雷達3.7311.42-1103.18002189中光學-2.764.27-1098.78600038中直股份4.474.15-1049.39688311盟升電子-3.101.98-1022.12300252金信諾-2.003.13-1012.02000733振華科技0.223.11-911.02600372中航機載1.531.63-895.92000697*ST煉石-3.992.36-885.03000547航天發展-1.461.04-860.93 注：本文係新聞報道，不構成投資建議，（文章來源：證券時報網）通信、申萬所屬行業中，今日淨流入資金1.96億元 ，漲幅居前的行業為石油石化、 主力資金淨流出的行業有24個，跌幅分別為2.27%、全天淨流出資金52.95億元，全天主力資金淨流入6.34億元，石油石化行業主力資金淨流入規模居首，兩市主力資金全天淨流出232.16億元，淨流出資金較多的還有電力設備、今日上漲的有96隻，電子行業主力資金淨流出規模居首 ，3100.58萬元。以資金流向數據進行統計， |
光算谷歌营销光算谷歌广告光算谷歌推广光算谷歌推广光算谷歌外鏈光算谷歌推广光算谷歌seo公司光算谷歌seo代运营光算谷歌seo光算谷歌外鏈光算谷歌外鏈https://synapse.patsnap.com/article/what-are-adam30-modulators-and-how-do-they-workhttps://synapse.patsnap.com/drug/013d41f73c9343cdb16ad263b99d6ec0https://synapse.patsnap.com/article/what-are-the-side-effects-of-trimetazidine-hydrochloridehttps://synapse.patsnap.com/blog/unleashing-the-power-of-risedronate-sodium-a-comprehensive-review-on-randd-breakthroughshttps://synapse.patsnap.com/drug/beda1ad7558d45bca78c146799b2b840https://synapse.patsnap.com/drug/eadd97c576967711a566cff0b0c1ef85https://synapse.patsnap.com/drug/1584493e04b644708f2c4875204ee980https://synapse.patsnap.com/article/what-is-the-mechanism-of-potassium-canrenoatehttps://synapse.patsnap.com/article/what-are-msh3-gene-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/article/what-are-%25CE%25B12c-ar-agonists-and-how-do-they-workhttps://synapse.patsnap.com/article/what-is-conbercept-used-forhttps://synapse.patsnap.com/drug/136f31aa31353edd84fbf43bda2f527chttps://synapse.patsnap.com/article/innovent-and-sanegenebio-start-phase-1-trial-with-first-dose-of-ibi3016https://synapse.patsnap.com/drug/8bf78dc4a79e47d9b48360370f26d80chttps://synapse.patsnap.com/drug/181f25fabae34b02b44b65681752c54ehttps://synapse.patsnap.com/blog/the-phase-1-clinical-trial-for-the-kras-g12d-inhibitor-mrtx1133-developed-by-mirati-has-been-launchedhttps://synapse.patsnap.com/article/what-is-rbt-1-used-forhttps://synapse.patsnap.com/article/what-are-the-therapeutic-applications-for-%25CE%25B1v%25CE%25B26-antagonistshttps://synapse.patsnap.com/blog/an-analysis-of-imm-27ms-randd-progress-and-its-clinical-results-presented-at-the-2024-aacr-annual-meetinghttps://synapse.patsnap.com/blog/an-overview-of-vertex-pharmaceuticalss-97-drug-pipeshttps://synapse.patsnap.com/article/what-is-the-mechanism-of-sennosideshttps://synapse.patsnap.com/drug/0b5f6577e43241b283f3fbe696472469https://synapse.patsnap.com/article/who-are-the-main-competitors-of-boehringer-ingelheimhttps://synapse.patsnap.com/article/neurogene-to-join-bmo-genetic-medicines-summithttps://synapse.patsnap.com/drug/7b916cd4a9cc4be0a62c1153a691f3bfhttps://synapse.patsnap.com/article/chemomab-therapeutics-to-attend-upcoming-scientific-conferenceshttps://synapse.patsnap.com/article/what-are-the-side-effects-of-azilsartanhttps://synapse.patsnap.com/drug/2acdd90558b349cf96bd04a9045b0313https://synapse.patsnap.com/drug/c8ccc15d960c41798d18f4ea5d6c7526https://synapse.patsnap.com/drug/f3cd36383d304d1ba5bf775dda6569d3